Match!
Aaron M. Goodman
University of California, San Diego
CancerPathologyImmunotherapyCancer researchMedicine
58Publications
10H-index
1,228Citations
What is this?
Publications 58
Newest
#1Timothy V. Pham (UCSD: University of California, San Diego)H-Index: 2
#2Amélie Boichard (UCSD: University of California, San Diego)H-Index: 5
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 7 authors...
Hydrophobic neo-antigens are more immunogenic because they are better presented by the major histocompatibility complex (MHC) and better recognized by T cells. Tumor cells can evade the immune response by expressing checkpoints such as PD-L1. Checkpoint blockade reactivates immune recognition and can be effective in diseases such as melanoma, which harbors a high tumor mutational burden (TMB). Cancers presenting low or intermediate TMB can also respond to checkpoint blockade, albeit less frequen...
Source
#1Philip CohenH-Index: 137
#2Mina NikanjamH-Index: 10
view all 10 authors...
Source
#1Daniella Klebaner (UCSD: University of California, San Diego)
#2Divya Koura (UCSD: University of California, San Diego)H-Index: 6
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 10
view all 6 authors...
Abstract Hepatosplenic T-cell Lymphoma (HSTCL) is a rare peripheral T-cell lymphoma that disproportionately affects individuals with a clinical history of immunosuppression. It carries a poor prognosis, and due to its rarity, there is no single or well-established treatment. We conducted the largest-to-date individual-level meta-analysis based on literature searches to determine the best induction therapy for HSTCL. We compared response rates and survival among patients who received “non-CHOP-ba...
Source
#1Kimberly M Lau (UCSD: University of California, San Diego)
#2Ila M. Saunders (UM: University of Montana)H-Index: 4
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 10
view all 3 authors...
IntroductionBlinatumomab is a CD19/CD3 bispecific T-cell engager (BiTE) antibody that simultaneously binds CD19 on the surface of B-cells and CD3 on the surface of T-cells, resulting in tumor cell ...
Source
#1Mina Nikanjam (UCSD: University of California, San Diego)H-Index: 10
#2Paul Riviere (UCSD: University of California, San Diego)H-Index: 3
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 6 authors...
High tumor mutational burden (TMB) predicts checkpoint blockade responsiveness, although the association with outcomes may be nuanced in certain tissue contexts. The correlation between TMB and cyt...
Source
#1Shumei Kato (UCSD: University of California, San Diego)H-Index: 18
#2Ryosuke Okamura (UCSD: University of California, San Diego)H-Index: 8
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 16 authors...
RAS alterations are often found in difficult-to-treat malignancies and are considered "undruggable." To better understand the clinical correlates and co-altered genes of RAS alterations, we used targeted next-generation sequencing (NGS) to analyze 1,937 patients with diverse cancers. Overall, 20.9% of cancers (405/1,937) harbored RAS alterations. Most RAS-altered cases had genomic co-alterations (95.3%, median: 3, range: 0-51), often involving genes implicated in oncogenic signals: PI3K pathway ...
Source
#1Gaurav Goyal (UAB: University of Alabama at Birmingham)H-Index: 9
#1Gaurav Goyal (UAB: University of Alabama at Birmingham)H-Index: 1
Last. Kazuhiro Toyama (UTokyo: University of Tokyo)H-Index: 4
view all 25 authors...
Erdheim-Chester disease (ECD) is a rare histiocytosis that was recently recognized as a neoplastic disorder owing to the discovery of recurrent activating MAP-kinase (RAS-RAF-MEK-ERK) pathway mutations. Typical findings of ECD include central diabetes insipidus, restrictive pericarditis, perinephric fibrosis, and sclerotic bone lesions. The histopathologic diagnosis of ECD is often challenging due to non-specific inflammatory and fibrotic findings on histopathologic review of tissue specimens. A...
5 CitationsSource
#1Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 10
#2Andrea Castro (UCSD: University of California, San Diego)H-Index: 1
Last. Edward D. Ball (UCSD: University of California, San Diego)H-Index: 40
view all 12 authors...
BACKGROUND: Immune checkpoint blockade (ICB) with antibodies inhibiting cytotoxic T lymphocyte-associated protein-4 (CTLA-4) and programmed cell death protein-1 (PD-1) (or its ligand (PD-L1)) can stimulate immune responses against cancer and have revolutionized the treatment of tumors. The influence of host germline genetics and its interaction with tumor neoantigens remains poorly defined. We sought to determine the interaction between tumor mutational burden (TMB) and the ability of a patient'...
1 CitationsSource
#1Neha Mehta-Shah (WashU: Washington University in St. Louis)H-Index: 10
#2Steven M. Horwitz (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 48
Last. Aaron M. Goodman (UCSD: University of California, San Diego)H-Index: 10
view all 34 authors...
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sezary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin...
1 CitationsSource
#1Amin Haghighat Jahromi (UCSD: University of California, San Diego)H-Index: 2
#2Matthew Zabel (UCSD: University of California, San Diego)
Last. Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 99
view all 8 authors...
123456